hackint0sh/New-Dataset huggingface dataset:
* Control-2 group: The participants were not provided with any programme, and the importance of weight loss was emphasised by the family physicians. Dietary and physical activity advice was given according to the recommendations in the Turkish Endocrine and Metabolism Association 2019 Obesity Diagnosis and Treatment Guide, and was followed up with phone calls at weeks 2, 4, 6, 8 and 10 over a 12-weeks. conditions: Obesity conditions: Life Style conditions: Lifestyle, Sedentary studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 152 type: ACTUAL name: intensive lifestyle measure: primary outcome sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Hacettepe University city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06321796 id: WCG IRB Protocol #20235847 briefTitle: Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders overallStatus: RECRUITING date: 2024-02-27 date: 2025-02 date: 2025-05 date: 2024-03-20 date: 2024-03-20 name: Gut-Brain-Axis Therapeutics Inc. class: OTHER name: Pitt Hopkins Research Foundation briefSummary: The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating patients with Pitt-Hopkins Syndrome (PTHS) and gastrointestinal problems (constipation, bloating, abdominal pain). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by 1 day of bowel cleanse using magnesium citrate, followed by 4 days of high dose MTP-101P with an antacid, followed by 12 weeks of a lower maintenance dose of MTP-101P with an antacid. conditions: Pitt Hopkins Syndrome studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Part 1: Randomized, Double-Blinded, Placebo-Controlled Treatment (14 weeks) Part 2: Open-Label Observation and Cross-over or Treatment Part 3: Follow Up (Group B Only) primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: MTP-101P name: Vancomycin name: Magnesium Citrate name: Antacid name: Placebo MTP-101P name: Placebo Vancomycin measure: Daily Stool Record (DSR) measure: Safety Measures (Adverse Events) measure: Gastrointestinal Symptom Rating Scale (GSRS) measure: Clinical Global Impression - Gastrointestinal (CGI-GI) measure: Clinical Global Impression - Pitt Hopkins (CGI-PTHS) measure: Parent Global Impressions - Pitt Hopkins: Change in Symptoms (PGI-PTHS-2-Change) measure: Gastrointestinal Symptoms common in Pitt Hopkins (GI-PTHS) measure: Revised Face Legs Activity Crying Consolability Pain Questionnaire (FLACC) measure: National Survey on treatment Effectiveness for Autism (NSTEA) - Overall Benefit measure: National Survey on treatment Effectiveness for Autism (NSTEA) - Overall Adverse E sex: ALL minimumAge: 5 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT facility: Autism/Asperger's Research Group at Arizona State University status: RECRUITING city: Tempe state: Arizona zip: 85287 country: United States name: James Adams, Phd role: CONTACT phone: 480-818-0741 email: jim.adams@asu.edu name: Jasmine Kirby, MS role: CONTACT phone: 4802343767 email: jkkirby1@gmail.com name: James Adams, PhD role: PRINCIPAL_INVESTIGATOR name: Rosa Krajmalnik-Brown, PhD role: SUB_INVESTIGATOR lat: 33.41477 lon: -111.90931 hasResults: False
nctId: NCT06321783 id: E-77082166-604.01.02-407303 briefTitle: Relationship Between Cervical Proprioception and Endurance With Hand-eye Coordination and Postural Control overallStatus: RECRUITING date: 2023-03-06 date: 2024-07-12 date: 2024-09-06 date: 2024-03-20 date: 2024-03-20 name: Gazi University class: OTHER briefSummary: The aim of our study is to investigate the relationship between cervical proprioception and cervical muscle endurance with hand-eye coordination and postural control in individuals with forward head posture (FHP) and to compare them with a control group with normal head posture. After the demographic information and physical characteristics of the individuals are recorded, their craniovertebral angles (CVA) will be measured and they will be assigned to Group 1 (forward head posture) or Group 2 (normal head posture). Then, the individuals' cervical proprioception, hand-eye coordination, postural control and cervical muscle endurance values will be measured respectively. Cervical muscle endurance will be evaluated last, taking into account possible muscle fatigue, in order not to affect other measurement results. The recorded values will be compared between groups and the relationship of cervical proprioception and muscle endurance with hand-eye coordination and postural control will be examined. All evaluations will be made by the same researcher. conditions: Forward Head Posture studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: Assessment measure: Cervical Proprioception measure: Hand-Eye Coordination measure: Postural Stability Test measure: Stability Limit Test measure: Modified Sensory Organization Test measure: Endurance of Cervical Muscles sex: ALL minimumAge: 18 Years maximumAge: 24 Years stdAges: ADULT facility: Gazi University status: RECRUITING city: Ankara state: Çankaya zip: 06490 country: Turkey name: Tuğçe Çoban, MSc role: CONTACT phone: +905454098540 email: fzttugce@yahoo.com lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06321770 id: 075-2022 briefTitle: Oral Supplementation With Active Collagen Peptides and Skin Health Improvement overallStatus: COMPLETED date: 2023-03-15 date: 2023-04-16 date: 2023-05-24 date: 2024-03-20 date: 2024-03-20 name: Gala Servicios Clinicos S.L. class: OTHER briefSummary: The present study aims to investigate the efficacy of daily supplementation with COLLinstant® LMW over a 6-week period in improving visible signs of aging. This in-cludes assessing its impact on skin wrinkle reduction, as well as its potential to en-hance skin elasticity and moisturization. COLLinstant® LMW was administered orally in a single-center, randomized, double-blind, placebo-controlled clinical trial. A sec-ondary objective involves comparing skin improvement, product satisfaction, and monitoring adverse events among middle-aged female volunteers. conditions: Facial Wrinkles conditions: Skin Hydration studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, Double-Blind, Placebo-Controlled Study primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Randomized, Double-Blind, Placebo-Controlled Study whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 80 type: ACTUAL name: Bioactive collagen peptides name: Placebo measure: Skin wrinkling volume (px^3) measure: Skin wrinkling area (px^2) measure: Skin wrinkling depth (px) measure: R0= Skin firmness (mm) measure: R2= gross elasticity (%) of the skin measure: R5= Skin net elasticity (%) measure: R7= Skin elastic recovery (%) measure: R9= Skin fatigue (mm) measure: Skin hydration (AU) measure: Subjective perception of product efficacy measure: Subjective perception of the organoleptic characteristics of the product measure: Opinion on the degree of satisfaction with the product sex: FEMALE minimumAge: 30 Years maximumAge: 60 Years stdAges: ADULT facility: GALA Laboratories city: Don Benito state: Badajoz zip: 06400 country: Spain lat: 38.95627 lon: -5.86162 hasResults: False
nctId: NCT06321757 id: EPIC30-PARIS briefTitle: PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients acronym: PARIS overallStatus: RECRUITING date: 2024-02-26 date: 2025-09-30 date: 2026-12-30 date: 2024-03-20 date: 2024-04-22 name: Fundación EPIC class: OTHER briefSummary: Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician. conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 501 type: ESTIMATED name: Percutaneous Coronary Intervention with DCB and DAPT measure: Effectiveness of DCB therapy measure: Cardiac death measure: All-cause mortality measure: Target vessel myocardial infarction measure: New target lesion revascularization (TLR) measure: Target vessel failure (TVF) measure: Major bleeding measure: Minor bleeding measure: 1-year MACE indicende (cardiac mortality, myocardial infarction, and new revascularization of the target lesion) in high-bleeding risk patients treated with a short dual antiplatelet treatment (7 days) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitario Clinico San Cecilio status: RECRUITING city: Granada zip: 18016 country: Spain lat: 37.18817 lon: -3.60667 facility: Hospital Universitario Juan Ramon Jimenez status: RECRUITING city: Huelva zip: 21005 country: Spain lat: 37.26638 lon: -6.94004 facility: Hospital Universitario de Leon status: RECRUITING city: León zip: 24071 country: Spain lat: 42.60003 lon: -5.57032 facility: Hospital Universitario Y Politecnico La Fe status: RECRUITING city: Valencia zip: 46026 country: Spain lat: 39.46975 lon: -0.37739 facility: Hospital Clinico Universitario de Valladolid status: RECRUITING city: Valladolid zip: 47003 country: Spain lat: 41.65518 lon: -4.72372 hasResults: False
nctId: NCT06321744 id: 2023/825 briefTitle: Study Evaluating the Feasibility of an Adapted Physical Activity Program During the Hospitalization Phase in Cancer Patients Undergoing Treatment acronym: PREVAPA overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-20 date: 2024-03-20 name: Centre Hospitalier Universitaire de Besancon class: OTHER briefSummary: This is a non-randomized, non-controlled feasibility study which will take place at the Besançon University Hospital in the conventional hospitalization department.
At the end of the initial assessment, an APA program supervised (individually and in a room) by an APA teacher will be offered to patients. The sessions will be offered daily to patients (maximum 5 times/week). They will last on average 20 minutes each depending on the fatigue, pain and fitness of the patients. The objectives pursued are mainly an improvement in functional independence and mobility. conditions: Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 32 type: ESTIMATED name: adapted physical activity program (APA Program) measure: Validate the feasibility of a supervised adapted physical activity (APA) program during the first 7 days of hospitalization in medical oncology for patients with cancer undergoing treatment measure: Describe the evolution of body composition measured by impedancemetry measure: Describe the evolution of physical parameters functional capacities measure: Describe the evolution of autonomy in daily life activities measure: Describe the evolution of muscular strength measure: Describe the evolution of the quality of life measure: Describe the evolution of motivation to practice physical activity measure: Tolerance with the APA program on perception of effort measure: Tolerance with the APA program on pain and fatigue measure: Tolerance with the APA program on fatigue measure: Compliance with the APA program measure: Criteria/reasons for non-participation, non-compliance, discontinuation of the intervention and study withdrawals measure: Patient satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321731 id: D5980R00096 briefTitle: Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain. acronym: ORESTES overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-11-30 date: 2024-11-30 date: 2024-03-20 date: 2024-03-20 name: AstraZeneca class: INDUSTRY briefSummary: The aim of the ORESTES study is to describe the characteristics of the COPD patients initiating Trixeo (BGF -budesonide/glycopyrronium/formoterol) in Spain and to assess their real-world outcomes up to 12 months afterwards.
For that purpose,a descriptive, observational, multi-centre, longitudinal, retrospective cohort study involving \~20 Spanish centres and aiming to include between 500 and 700 patients, has been designed. conditions: Chronic Obstructive Pulmonary Disease (COPD) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 500 type: ESTIMATED measure: Annualized rate of exacerbations after BGF initiation measure: Demographic and clinical profile of patients initiating BGF. measure: Lung Function after BGF initiation measure: Eosinophils count after BGF initiation measure: Persistence to treatment (BGF) measure: Need for rescue medication after BGF initiation measure: Use of oral corticosteroids (OCS) after BGF initiation measure: HCRUs related to COPD after BGF initiation measure: Annualized rate of severe cardiovascular (CV)-related outcomes after initiation of BGF. measure: Mortality (% and time to event) after BGF initiation sex: ALL minimumAge: 40 Years maximumAge: 130 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321718 id: 04-2023-200629 briefTitle: Pericapsular Nerve Group Block vs Supra Inguinal Fascia Iliaca Compartment Block overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-03-01 date: 2025-04-01 date: 2024-03-20 date: 2024-03-20 name: Assiut University class: OTHER briefSummary: This study aims to assess the efficacy of PENG block performed with LFCN block in controlling postoperative pain and promoting motor function recovery and to compare its effectiveness with S-FICB. conditions: Pain, Postoperative studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 96 Patients will be enrolled. Choice of type of anesthesia will be established according to every individual patient, but spinal anesthesia will be preferred over general anesthesia. The block will be administered under supervision of the supervisor senior staff before induction of anesthesia. 2 groups well be assessed
2. The second group (B): S-FICB primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Through website computer program randomization program to distribute cases into two groups using their order number whoMasked: PARTICIPANT count: 96 type: ESTIMATED name: PENG + LFCN block versus S-FICB measure: recording time for "return of full muscle power" measure: • The degree of hip flexion on the operative side measure: • Static and dynamic pain scores. measure: postoperative nausea and vomiting (PONV) scale measure: • The number of rescue analgesia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321705 id: CS1-004 briefTitle: Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension overallStatus: AVAILABLE date: 2024-03-20 date: 2024-03-20 name: Cereno Scientific AB class: INDUSTRY name: Worldwide Clinical Trials name: Abbott briefSummary: CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study is to evaluate long-term safety and tolerability of continued treatment with CS1. conditions: Pulmonary Arterial Hypertension studyType: EXPANDED_ACCESS name: CS1 sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fredrik Frick status: AVAILABLE city: Gothenburg country: Sweden name: Fredrik Frick role: CONTACT phone: +46725479566 email: Fredrik.Frick@cerenoscientific.com lat: 57.70716 lon: 11.96679 hasResults: False
nctId: NCT06321692 id: IEO 1003 briefTitle: Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications overallStatus: RECRUITING date: 2019-10-09 date: 2024-12-31 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: European Institute of Oncology class: OTHER briefSummary: This study is for patients with neuroendocrine tumours (NET) with or without carcinoid syndrome followed by NET Unit of European Institute of Oncology.
The objective of the trial is to evaluate biochemical markers of myocardial injury (high-sensitive troponins), haemodyinamic markers (pro-brain natriuretic peptide (BNP), N-terminal (NT)-BNP (NT-proBNP)), and markers of fibrosis (Suppression of Tumorigenicity 2 (ST2) in patients with neuroendocrine tumours (NET) with or without carcinoid syndrome. conditions: Neuroendocrine Tumors studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: Evaluation of blood levels of biomarkers of cardiac damage measure: blood levels of biomarkers of cardiac damage measure: blood levels of biomarkers of hemodynamic impairment measure: blood levels of biomarkers of cardiac fibrosis measure: Correlation between the levels of the biomarkers and the presence/entity of cardiac involvement sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Daniela Cardinale, MD role: CONTACT email: daniela.cardinale@ieo.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06321679 id: IEO 1269 briefTitle: Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone acronym: RESPECT overallStatus: RECRUITING date: 2020-07-03 date: 2024-12-31 date: 2027-12-31 date: 2024-03-20 date: 2024-03-20 name: European Institute of Oncology class: OTHER briefSummary: This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone.
This is a monocentric, prospective observational study. conditions: Castration-resistant Prostate Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Imaging evaluation measure: Time to disease progression in bone metastasis identify by WB-MRI sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IEO Istituto Europeo di Oncologia status: RECRUITING city: Milan zip: 20141 country: Italy name: Giuseppe Petralia role: CONTACT email: giuseppe.petralia@ieo.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06321666 id: IEO 0986 briefTitle: Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone acronym: RESPECT-MI overallStatus: ACTIVE_NOT_RECRUITING date: 2019-09-12 date: 2024-12-31 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: European Institute of Oncology class: OTHER briefSummary: This is a non randomized, single arm study, where each patient will undergo imaging with Computed Tomography (CT) and Whole-body magnetic resonance imaging (WB-MRI) at different timepoint. The primary endpoint is time to progression as documented by CT or WB-MRI. conditions: Metastatic Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 58 type: ACTUAL name: WB-MRI measure: Proportion of disease progression in bone metastasis identified by WB-MRI prior to CT scan sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IEO Istituto Europeo di Oncologia city: Milan zip: 20141 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06321653 id: IEO 0953 briefTitle: Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes acronym: AXILL-ART overallStatus: RECRUITING date: 2019-04-18 date: 2024-12-31 date: 2027-12-31 date: 2024-03-20 date: 2024-03-20 name: European Institute of Oncology class: OTHER briefSummary: In this observational prospective studi patients with invasive breast cancer no more than 5 cm and clinically node negative, scheduled for conservative surgery and Sentinel Node Biopsy (SNB), are enrolled in the protocol if they have 1-2 sentinel lymphnodes (SLNs) with macrometastases. SLN status will be checked on definitive sections. conditions: Arm Lymphedema conditions: Breast Cancer conditions: Radiotherapy Side Effect studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Hypofractionated radiotherapy scheme measure: Percentage of patients with arm lymphedema measure: Evaluation of cute locoregional toxicity at breast and axilla measure: Evaluation of chronic toxicity at breast and axilla measure: Disease free survival measure: Overall survival measure: Quality of life (QoL) in order to evaluate pain, itching and burning at breast or axilla sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Maria Cristina Leonardi role: CONTACT phone: +39 02 94372156 lat: 45.46427 lon: 9.18951 hasResults: False